Can patients with coronary heart disease receive the COVID-19 vaccine?

Whether patients with coronary heart disease can receive the COVID-19 vaccine should be determined based on the stability of their condition and overall health. If any discomfort occurs, prompt medical consultation is recommended. The detailed analysis is as follows:

Patients with stable coronary heart disease who have not experienced acute events such as angina or myocardial infarction in the past three months, whose cardiac function is normal, and who have no contraindications to vaccination may receive the COVID-19 vaccine after evaluation by a physician. These patients are in a stable condition, and vaccination can effectively reduce the risk of infection. The vaccine components will not adversely affect cardiovascular health during the stable phase. After vaccination, patients should remain on-site for 30 minutes of observation.

Patients currently experiencing an acute episode of coronary heart disease—such as frequent angina, recent acute myocardial infarction without full recovery, severely impaired cardiac function, or complications such as uncontrolled hypertension—should not receive the vaccine. During this period, the patient's physical tolerance is poor, and vaccination could worsen the condition or trigger serious adverse reactions. Priority should be given to treating the underlying disease; vaccination eligibility can be reassessed once the condition stabilizes.

Patients should continue taking prescribed medications regularly before and after vaccination and must not discontinue medication without guidance. Maintain a light diet, avoid emotional stress and strenuous exercise. If symptoms such as chest pain or chest tightness occur after vaccination, immediately inform healthcare providers and seek medical attention.